Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Balance Sheet

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	32.63	30.95	20.01	22.99	19.36	49.65
Cash & Short-Term Investments	32.63	30.95	20.01	22.99	19.36	49.65
Cash Growth	62.27%	54.71%	-12.96%	18.72%	-61.01%	3.26%
Receivables	33.23	31.16	23.53	28.73	21.71	28.18
Inventory	10.1	11.43	12.14	8.51	10.85	16.34
Prepaid Expenses	5.15	5.64	5.1	5.43	7.38	9.78
Restricted Cash	-	-	-	-	-	0.25
Other Current Assets	-	-	1.12	5.43	0.63	1.04
Total Current Assets	81.11	79.18	61.89	71.08	59.93	105.23
Property, Plant & Equipment	1.51	1.59	1.52	3.61	6.3	8.7
Goodwill	-	-	-	-	-	65.8
Other Intangible Assets	41.43	42.2	52.45	57.44	70.63	85.46
Long-Term Deferred Tax Assets	-	0.25	0.76	1.38	-	-
Other Long-Term Assets	0.94	0.95	1.47	2.96	0.77	0.47
Total Assets	124.99	124.18	118.1	136.46	137.62	265.67
Accounts Payable	12.34	10.6	10.31	12.55	10.99	19.26
Accrued Expenses	16.25	15.26	22.26	24.54	25.71	30.72
Short-Term Debt	14.87	9.06	2.4	1.56	3.81	7.93
Current Portion of Long-Term Debt	1.86	1.86	1.86	-	-	16.57
Current Portion of Leases	0.2	0.14	0.71	1.34	0.1	0.1
Other Current Liabilities	20.47	26.15	24.69	29.02	23.84	34.86
Total Current Liabilities	65.99	63.06	62.23	69.02	64.44	109.44
Long-Term Debt	10.45	10.9	10.88	14.71	14.2	-
Long-Term Leases	1.02	0.99	0.58	0.83	0.08	0.18
Long-Term Deferred Tax Liabilities	-	0.25	0.76	1.38	-	-
Other Long-Term Liabilities	24.35	30.02	15.94	11.17	14.59	18.48
Total Liabilities	101.82	105.21	90.38	97.11	93.32	128.1
Common Stock	0	0	0	0	-	0
Additional Paid-In Capital	354.74	352.5	347.69	343.49	331.39	315.86
Retained Earnings	-331.57	-333.54	-319.97	-304.13	-287.08	-178.3
Total Common Equity	23.17	18.97	27.72	39.36	44.31	137.57
Shareholders' Equity	23.17	18.97	27.72	39.36	44.31	137.57
Total Liabilities & Equity	124.99	124.18	118.1	136.46	137.62	265.67
Total Debt	28.4	22.94	16.42	18.45	18.19	24.78
Net Cash (Debt)	4.23	8.02	3.59	4.53	1.17	24.87
Net Cash Growth	119.86%	123.38%	-20.87%	286.86%	-95.29%	-46.03%
Net Cash Per Share	0.59	1.28	0.65	1.36	0.80	29.70
Filing Date Shares Outstanding	10.19	9.91	6.17	5.53	3.12	1.38
Total Common Shares Outstanding	9.91	8.98	5.97	5.52	1.93	1.37
Working Capital	15.12	16.12	-0.34	2.06	-4.51	-4.2
Book Value Per Share	2.34	2.11	4.64	7.13	22.97	100.08
Tangible Book Value	-18.26	-23.24	-24.74	-18.08	-26.32	-13.7
Tangible Book Value Per Share	-1.84	-2.59	-4.14	-3.28	-13.65	-9.97
Machinery	1.07	1.08	2.78	4.29	4.45	5
Construction In Progress	-	-	-	0.11	-	0.2
Leasehold Improvements	0.16	0.16	0.04	1	1	0.96

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q